Antibodies – Talk Bio

German cancer antibody biotech eyes SPAC as route to Nasdaq

15 hours ago talkbio0Tagged Antibodies, German language, Nasdaq, SPAC, Veraxa

Veraxa, Antibodies, SPAC, German language, Nasdaq

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

3 days ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab

Isomorphic Labs Secures $600M to Accelerate AI-Powered Drug Discovery

3 weeks ago talkbio0Tagged Antibodies, Aortic Valve Insufficiency, Demis, expansion, Hassabis, Isomorphous, Laboratory test finding, U.S.

AI drug discovery, Isomorphic Labs, Demis Hassabis, funding round, antibodies, US expansion

Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

3 months ago talkbio0Tagged Antibodies, Beyfortus, blockbuster sales, Growth, Infant, Market, Protection, Respiratory syncytial virus, sanofi, U.S.

Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus

Leap Therapeutics’ Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials

3 months ago talkbio0Tagged Antibodies, Clinical Trials, DKK1 gene, LEAP, Malignant neoplasm of stomach, Performance

Leap Therapeutics, DKK1 Antibody, Gastric Cancer, Clinical Trials, Stock Performance

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

3 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig

4 months ago talkbio0Tagged 5'-NUCLEOTIDASE, Antibodies, Antibodies, Bispecific, Givastomig, I-Mab, Immunotherapy for cancer, metastatic gastric cancers, pipeline, reshuffle, Uliledlimab

I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers

Regeneron Advances Anticoagulant Antibody Pair to Late-Stage Testing

4 months ago talkbio0Tagged Antibodies, Anticoagulants, late-stage testing, Regeneron, REGN7508, REGN9933

Regeneron, anticoagulant, antibody, late-stage testing, Factor XI, REGN7508, REGN9933

Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results

4 months ago talkbio0Tagged Antibodies, Crohn 's disease, duvakitug, Gastrointestinal Diseases, Immunology, Inflammatory Bowel Diseases, Precision Medicine, TNFSF15 gene, Ulcerative Colitis

Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases

Viridian’s Veligrotug Demonstrates Efficacy in Second Pivotal Study for Thyroid Eye Disease

4 months ago talkbio0Tagged Antibodies, Clinical Trials, IGF1R protein, human, Phase 3, THRIVE-2, Thyroid associated opthalmopathies, Veligrotug, Viridian

Thyroid Eye Disease, Veligrotug, Viridian Therapeutics, Phase 3 Clinical Trial, THRIVE-2, IGF-1R Antibody